Oxxon In-Licenses Xenova Platform, Cancer Product

Oxxon In-Licenses Xenova Platform, Cancer Product

Chelsea Therapeutics' First Round: $14.5M For Antifolate Drug Studies

Chelsea Therapeutics' First Round: $14.5M For Antifolate Drug Studies

Sepracor Getting $20M Worth Of Acadia Shares In CNS Deal

Sepracor Getting $20M Worth Of Acadia Shares In CNS Deal

Saving Cash, Refocusing, Isis Cuts Work Force By 40 Percent

Saving Cash, Refocusing, Isis Cuts Work Force By 40 Percent

Depomed Bringing In $22M For Trials, Marketing Of GR Products

Depomed Bringing In $22M For Trials, Marketing Of GR Products